Table 1 Clinical trials of CMT in stage... | American Society of Hematology

Table 1

Clinical trials of CMT in stage I or II Hodgkin lymphoma

	Accrual years	Protocol	N	Median follow-up, mo	Treatment	OS, %	OS, yr	P	FFDP/FFTF/EFS, %	FFDP/FFTF/EFS, yr	P
EORTC¹⁶	1993-1999	H8-F	542	92	STNI	92	10	.001	68	10	< .001
					MOPP-ABV × 3 + STNI	97	10		93	10
		H8-U	996	89	MOPP-ABV × 6 + IFRT	88	10	.93	82	10	.8
					MOPP-ABV × 4 + IFRT	85	10		80	10
					MOPP-ABV × 4 + STNI	84	10		80	10
INT¹⁷	1990-1996		136	116	ABVD × 4 + STNI	96	12	NS	93	12	NS
					ABVD × 4 + IFRT	94	12		94	12
GHSG¹	1998-2003	HD10	1190	91 (OS);	4ABVD + 30 Gy IFRT	94	8	NS	87	8	NS
				79 (FFTF)	4ABVD + 20 Gy IFRT	95	8		90	8
					2ABVD + 30 Gy IFRT	94	8		86	8
					2ABVD + 20 Gy IFRT	95	8		86	8
GHSG²³	1998-2003	HD11	1395	82	4ABVD + 30 Gy IFRT	94	5	NS	85	5
					4ABVD + 20 Gy IFRT	94	5		81	5	.03*
					4BEACOPP + 30 Gy IFRT	95	5		87	5
					4BEACOPP + 20 Gy IFRT	95	5		87	5
Stanford²⁴	1996-2004	G4	87	127	Stanford V × 8 wk + 30 Gy IFRT	94	10		94	10

	Accrual years	Protocol	N	Median follow-up, mo	Treatment	OS, %	OS, yr	P	FFDP/FFTF/EFS, %	FFDP/FFTF/EFS, yr	P
EORTC¹⁶	1993-1999	H8-F	542	92	STNI	92	10	.001	68	10	< .001
					MOPP-ABV × 3 + STNI	97	10		93	10
		H8-U	996	89	MOPP-ABV × 6 + IFRT	88	10	.93	82	10	.8
					MOPP-ABV × 4 + IFRT	85	10		80	10
					MOPP-ABV × 4 + STNI	84	10		80	10
INT¹⁷	1990-1996		136	116	ABVD × 4 + STNI	96	12	NS	93	12	NS
					ABVD × 4 + IFRT	94	12		94	12
GHSG¹	1998-2003	HD10	1190	91 (OS);	4ABVD + 30 Gy IFRT	94	8	NS	87	8	NS
				79 (FFTF)	4ABVD + 20 Gy IFRT	95	8		90	8
					2ABVD + 30 Gy IFRT	94	8		86	8
					2ABVD + 20 Gy IFRT	95	8		86	8
GHSG²³	1998-2003	HD11	1395	82	4ABVD + 30 Gy IFRT	94	5	NS	85	5
					4ABVD + 20 Gy IFRT	94	5		81	5	.03*
					4BEACOPP + 30 Gy IFRT	95	5		87	5
					4BEACOPP + 20 Gy IFRT	95	5		87	5
Stanford²⁴	1996-2004	G4	87	127	Stanford V × 8 wk + 30 Gy IFRT	94	10		94	10

FFDP indicates freedom from disease progression; INT, Istituto Nazionale Tumori; and NS, not significant.

Comparison of PFS for 4ABVD + 20 Gy IFRT vs 4ABVD + 30 Gy IFRT.